×
Customize
?
Start
Cancer Types
Quick Links
Award Programs
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
Kidney Cancer
Katie Kosko
Patients with advanced renal cell carcinoma have new first-line therapy options.
Kristie L. Kahl
The Food and Drug Administration approved the combination use of Bavencio plus Inlyta for the first-line treatment of patients with advanced renal cell carcinoma.
Kristie L. Kahl
With the growing price of cancer treatment, researchers evaluated the cost-effectiveness of the new standard-of-care in frontline metastatic renal cell carcinoma.
Katie Kosko
Kidney cancer survivors who follow recommendations for physical activity experience improved quality of life, but few individuals adhere to the guidelines, according to recent findings.
Alexandra Guadagno
With patient resistance to single-agent immunotherapies in the treatment of advanced renal cell carcinoma, new combination therapies are needed in the frontline setting.
Katie Kosko
A person’s pre-existing mental state may negatively influence their health, but professional support can help maintain the best mindset, say researchers.
Gina Columbus
The Food and Drug Administration approved Keytruda in combination with Inlyta for the frontline treatment of patients with advanced renal cell carcinoma.
Kristie L. Kahl
The combination use of Keytruda plus Inlyta significantly improved survival outcomes among patients with previously untreated advanced renal cell carcinoma – the most common type of kidney cancer.
Brielle Benyon
There is still work to do in the field of molecular diagnosis for renal cell carcinoma, according to David I. Quinn, MBBS, Ph.D., FRACP, FACP.
Mario Snozl, M.D.
An expert discusses the evolving treatments for renal cell carcinoma (RCC) over the last decade, as well as the future role of immunotherapies for patients with RCC.